International Journal of Endocrinology and Metabolism

Published by: Kowsar

Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients

Jun Iwamoto 1 , *
Author Information
1 Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan
Article information
  • International Journal of Endocrinology and Metabolism: June 01, 2012, 10 (3); 573-575
  • Published Online: June 30, 2012
  • Article Type: Letter
  • Received: April 30, 2012
  • Revised: May 1, 2012
  • Accepted: May 2, 2012
  • DOI: 10.5812/ijem.5367

To Cite: Iwamoto J. Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients, Int J Endocrinol Metab. 2012 ; 10(3):573-575. doi: 10.5812/ijem.5367.

Copyright © 2012, Research Institute For Endocrine Sciences and Iran Endocrine Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando S, et al. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int J Endocrinol Metab. 2012; 10: 464-9[DOI]
  • 2. Iwamoto J, Sato Y, Takeda T, Matsumoto H. Bone quality and vitamin K2 in type 2 diabetes: review of preclinical and clinical studies. Nutr Rev. 2011; 69(3): 162-7[DOI][PubMed]
  • 3. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. 2007; 18(12): 1675-81[DOI][PubMed]
  • 4. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int. 2009; 85(3): 228-34[DOI][PubMed]
  • 5. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7): 637-45[DOI][PubMed]
  • 6. Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res. 2004; 19(5): 764-72[DOI][PubMed]
  • 7. Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, Stehman-Breen C, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007; 18(1): 282-6[DOI][PubMed]
  • 8. Kinsella S, Chavrimootoo S, Molloy MG, Eustace JA. Moderate chronic kidney disease in women is associated with fracture occurrence independently of osteoporosis. Nephron Clin Pract. 2010; 116(3)-62[DOI][PubMed]
  • 9. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008; 74(6): 721-31[DOI][PubMed]
  • 10. Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006; 17(11): 3223-32[DOI][PubMed]
  • 11. West SL, Lok CE, Jamal SA. Fracture Risk Assessment in Chronic Kidney Disease, Prospective Testing Under Real World Environments (FRACTURE): a prospective study. BMC Nephrol. 2010; 11: 17[DOI][PubMed]
  • 12. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab. 1988; 67(5): 876-81[DOI][PubMed]
  • 13. Jamal SA, West SL, Miller PD. Bone and kidney disease: diagnostic and therapeutic implications. Curr Rheumatol Rep. 2012; 14(3): 217-23[DOI][PubMed]
  • 14. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008; 19(7): 1430-8[DOI][PubMed]
  • 15. Melamed ML, Blackwell T, Neugarten J, Arnsten JH, Ensrud KE, Ishani A, et al. Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney Int. 2011; 79(2): 241-9[DOI][PubMed]
  • 16. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166(5): 495-505[DOI][PubMed]
  • 17. Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin. 2009; 25(5): 1057-72[DOI][PubMed]
  • 18. Saito M, Marumo K, Soshi S, Kida Y, Ushiku C, Shinohara A. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int. 2010; 21(4): 655-66[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments